TPMT Antibody
- Known as:
- TPMT Antibody
- Catalog number:
- 32120
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Signalway
- Gene target:
- TPMT Antibody
Related genes to: TPMT Antibody
- Gene:
- TPMT NIH gene
- Name:
- thiopurine S-methyltransferase
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- 6p22.3
- Locus Type:
- gene with protein product
- Date approved:
- 1993-08-25
- Date modifiied:
- 2019-04-23
Related products to: TPMT Antibody
Related articles to: TPMT Antibody
- Transdermal fentanyl (TDF) is widely used for moderate-to-severe cancer pain, yet substantial variability in fentanyl exposure, analgesic response, and tolerability remains incompletely explained by clinical factors. We evaluated whether pharmacogenetic variability is associated with pharmacokinetic parameters and clinical outcomes in cancer patients receiving TDF. - Source: PubMed
Publication date: 2026/08/17
Angelini LuciaAzzali IreneCarlini AndreaAndrisano VincenzaMontanari SerenaDall'agata MoniaSimonetti GiorgiaBochicchio Maria TeresaPaganelli MatteoValenti VanessaCravero PaolaCurrà MargheritaPetrini LindaDonati Costanza MariaMorganti Alessio GArdizzoni AndreaCorli Oscar EdoardoMaltoni Marco CesareRossi RominaRicci Marianna - Sarcopenia is common among patients with cirrhosis and is closely associated with poor prognosis. However, the value of different methods for assessing sarcopenia in predicting mortality risk in patients with cirrhosis remains controversial. This study aims to systematically evaluate the predictive ability of different methods for measuring sarcopenia regarding mortality risk in patients with cirrhosis. - Source: PubMed
Publication date: 2026/08/13
Xie WenruiShi WanxinXu RunbingShang ZimengHuo GuangyuanZhang ZheYang Zhiyun - : Childhood and adolescent acute lymphoblastic leukemia (ALL) survival outcomes have improved significantly, but treatment-related toxicities (TRTs) remain a major concern affecting dose intensity and quality of life. Germline pharmacogenetic variations contribute to inter-individual differences in chemotherapy response, yet consistent replication of associations has been limited by differences in treatment protocols, ethnic backgrounds, and toxicity definitions. : This systematic review and meta-analysis (PROSPERO CRD42021229748) included 68 studies in the qualitative synthesis, with 42 high-quality studies undergoing structured synthesis and, where appropriate, quantitative meta-analysis. Studies focused on the toxicities of thiopurines, methotrexate, glucocorticoids, vincristine, and asparaginase. : Meta-analyses showed strong evidence linking the rs116855232 variant to thiopurine-induced myelosuppression (OR 19.0, 95% CI 1.6-224; I = 86.5%) and a significant association between the enhancer repeat polymorphism and osteonecrosis (OR 6.66, 95% CI 3.67-12.11; I = 0%). In contrast, variants and polymorphisms showed no significant associations with methotrexate-induced myelosuppression or osteonecrosis, respectively. Narrative synthesis highlighted clinically actionable associations: and with thiopurine toxicity; with vincristine neuropathy; and haplotypes with asparaginase hypersensitivity. Population allele frequency comparisons (IndiGenomes, gnomAD, UK Biobank) showed strong concordance (r = 0.919-0.997), supporting the broad generalisability of identified variants, which remains to be evaluated prospectively. The main limitations included heterogeneous toxicity definitions, non-uniform genetic models, evolving treatment protocols, population heterogeneity, and a lack of harmonised reporting. : The review supports routine and genotyping and highlights the need for harmonised definitions, multi-ethnic studies, standardised data representation, and prospective validation. A literature-based candidate gene list for future PGx association studies was generated. - Source: PubMed
Publication date: 2026/08/01
Chenchula SantennaSrinivasamurthy Suresh KumarVincent VinnyfredThakkar HimaniGanguly ShuvadeepKayal SmitaKeerthivasagam SwaminathanRamamoorthy JaikumarSharma SwetambriMurugadoss KamaliSingh ArchnaPushpam DeepamMathaiyan JayanthiJolly BaniScaria VinodGloor YvonneBaleydier FredericBakhshi SameerDubashi BiswajitAnsari MarcUppugunduri Chakradhara Rao S - We describe how our in-house bioinformatics platform, Flype, has evolved from being a variant repository to an enterprise role as an electronic medical record (EMR) content provider, powering molecular pathology reporting, pharmacogenomics reporting, sending discrete data to our EMR, aggregating internal and external molecular test results and powering our molecular tumor board (MTB). In response to critical pain points, we developed Docket, a sample tracking system in Flype, which manages multiple individual in-house molecular tests for NGS assays, pharmacogenomic (PGX) assays and additional molecular testing. To help with interpretation and integration of all internal and external assays, we developed a clinical outcomes view in Flype. To improve the efficiency of our molecular pathologists reporting results, we developed Convo 2.0, which integrates OncoKB interpretations and other information. Flype can also be used by our pathologists to submit patient molecular results to NCI's ComboMATCH and retrieve clinical trial recommendations. Flype was used during our Kellogg Cancer Genomic Initiative for reporting PGX integration, MTB review and integration of EMR prescription information with internal and external molecular test results. Integrating PGX results led to several recommendations against the use of drugs metabolized by, for example, or , along with warnings about altered pain relief. Enhancements in report sign-out and the use of file transfer scripts have led to reduced turnaround time. Flype supports hundreds of users performing different roles in molecular diagnostics. We discuss lessons learned adapting our software to support continuously changing test requirements. - Source: PubMed
Publication date: 2026/08/10
Helseth Donald LMiller NicholasYang MathewWittich HenryZhao QinWerth TomSabatini Linda MAlikhan MirParilla MeganKaur AmandeepYang XiaoyanMangold Kathy ABouma MichaelDunnenberger Henry MWake Dyson TSereika AnnetteMoorthy GayathriHulick Peter JKaul Karen LKhandekar Janaradan D - Pharmacogenetics plays an increasingly important role in oncology by supporting individualized therapeutic strategies based on patient genetic profiles. ClinicalTrials.gov provides a valuable platform for evaluating global trends in pharmacogenetic anticancer clinical trials. This systematic review aimed to evaluate pharmacogenetic-focused anticancer clinical trials registered on ClinicalTrials.gov and summarize trends in study design, cancer types, targeted biomarkers, therapeutic interventions, and geographic distribution. - Source: PubMed
Ashour Ahmed MAlhayyan AliahAlhayyan Rawan